Clinical bottom line
Refractory nocturnal polyuria (NP) in adults, characterized by excessive nighttime urine production leading to bothersome nocturia, remains a challenging condition to manage. Recent evidence supports the cautious use of low-dose desmopressin as a novel therapeutic option, particularly in elderly men, demonstrating efficacy in reducing nocturnal urine volume and nocturia episodes with an acceptable safety profile. However, patient selection and monitoring for hyponatremia are critical. Emerging data also suggest that understanding individual diuretic patterns and comorbidities such as hypertension may optimize treatment outcomes. Overall, novel therapies targeting NP warrant further validation but offer promising adjuncts to current management strategies.
What the evidence shows
Nocturnal polyuria is a common contributor to nocturia, defined by a disproportionate increase in nighttime urine output relative to total daily urine volume. Osamu et al. (2007) highlighted the role of blood pressure fluctuations in exacerbating nocturnal polyuria, suggesting that cardiovascular factors may influence nocturnal diuresis patterns. This insight supports a more tailored approach considering comorbid conditions.
Desmopressin, a synthetic vasopressin analogue, has been extensively studied for NP management. Furuta et al. (2024) reported on the long-term safety and efficacy of low-dose desmopressin in men over 80 years old, demonstrating sustained reductions in nocturnal urine volume and nocturia frequency with minimal adverse events. Similarly, Chu et al. (2025) evaluated an initial 0.1 mg dose of desmopressin in the oldest-old male population, confirming its tolerability and efficacy in reducing nocturnal voids.
Kurose et al. (2023) investigated predictors of response to long-term desmopressin therapy, finding that baseline nocturnal urine volume and renal function influenced treatment outcomes. Their data support individualized dosing and careful patient selection to maximize benefit while minimizing risks such as hyponatremia.
The 2017 review "Understanding and managing nocturnal polyuria" consolidates these findings, emphasizing the importance of accurate diagnosis, including quantification of nocturnal urine production, and the role of desmopressin as a first-line pharmacological agent when conservative measures fail.
Caveats and uncertainty
Despite promising results, several uncertainties remain. Most desmopressin studies focus on elderly men, limiting generalizability to women and younger adults with NP. The risk of hyponatremia, particularly in older patients or those with impaired renal function, necessitates vigilant electrolyte monitoring, which may limit widespread use.
Long-term safety data beyond several years are sparse, and the optimal dosing regimen to balance efficacy and safety is not fully established. Additionally, the interplay between nocturnal polyuria and comorbidities such as hypertension and sleep disorders requires further elucidation to refine treatment algorithms.
There is also a lack of robust randomized controlled trials comparing desmopressin with other emerging therapies or combination approaches, leaving gaps in evidence for alternative or adjunctive treatments.
How this may change practice
Clinicians managing refractory nocturnal polyuria should consider low-dose desmopressin as a viable therapeutic option, especially in elderly men with documented nocturnal polyuria who have not responded to lifestyle modifications. Prior to initiation, thorough assessment including voiding diaries and serum sodium measurement is essential.
Recognition of contributory factors such as blood pressure variability may prompt integrated management involving cardiovascular optimization. Individualized dosing and close monitoring can mitigate risks and improve patient outcomes.
Future incorporation of predictive markers for desmopressin response, as suggested by recent studies, may enhance personalized therapy. Awareness of current evidence can guide shared decision-making and improve quality of life for patients burdened by nocturia due to nocturnal polyuria.